[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344794-105":59,"doc-detail-344794-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","splicing-factor-3a-subunit-1-promotes-colorectal-cancer-growth-via-anti-apoptotic-effects-of-syntaxin12","Splicing Factor 3a Subunit 1 Promotes Colorectal Cancer Growth via Anti-Apoptotic Effects of Syntaxin12","","RNA dysregulation driven by aberrant RNA-binding proteins (RBPs) is linked to tumorigenesis, yet mechanisms for individual RBPs remained unclear. This study shows that downregulation of Splicing factor 3A1 (SF3A1) suppresses proliferation of colorectal cancer (CRC) cells with limited cytotoxicity in non-cancerous epithelial cells. In an HCT116 xenograft model, SF3A1 limits apoptosis through TUNEL, PARP immunoblotting, and caspase-3/7 activity changes. Transcriptome analysis and RNA immunoprecipitation identify Syntaxin 12 (STX12) as a downstream effector, where STX12 knockdown triggers apoptosis selectively in malignant cells and SF3A1 stabilizes STX12 mRNA, defining an SF3A1–STX12 axis as a targeted therapeutic opportunity for CRC.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/splicing-factor-3a-subunit-1-promotes-colorectal-cancer-growth-via-anti-apoptotic-effects-of-syntaxin12/344794/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/splicing-factor-3a-subunit-1-promotes-colorectal-cancer-growth-via-anti-apoptotic-effects-of-syntaxin12/344794.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does SF3A1 affect colorectal cancer cell growth and apoptosis?","Question",{"text":112,"@type":113},"SF3A1 downregulation markedly suppresses CRC cell proliferation and promotes apoptotic signaling. Multiple apoptosis assays indicate that SF3A1 inhibits apoptosis in CRC cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What downstream molecule links SF3A1 to apoptosis resistance?",{"text":117,"@type":113},"Syntaxin 12 (STX12) is identified as a downstream effector of SF3A1. STX12 knockdown induces apoptosis in CRC cells, and SF3A1 knockdown reduces STX12 mRNA levels.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is the apoptosis effect described as selective for malignant cells?",{"text":121,"@type":113},"STX12 knockdown induces apoptosis in CRC cells but does not affect viability of non-cancerous epithelial HCEC-1CT cells. SF3A1 also shows minimal cytotoxicity in non-cancerous epithelial cells upon downregulation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344794,1790333806,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Article  \nSplicing Factor 3a Subunit 1 Promotes Colorectal Cancer Growth via Anti-Apoptotic Effects of Syntaxin12  \nTakahiro Sasaki 1, Hiroaki Konishi 2, *, Tatsuya Dokoshi 3, Aki Sakatani 3, Hiroki Tanaka 4, Koji Yamamoto 2, Keitaro Takahashi 1, Katsuyoshi Ando 1, Nobuhiro Ueno 1, Shin Kashima 1, Kentaro Moriichi 1, Hiroki Tanabe 1, Toshikatsu Okumura 1 and Mikihiro Fujiya 1,2,3  \nAcademic Editor: Sonia Melino  \nReceived: 25 November 2025  \nRevised: 8 January 2026  \nAccepted: 22 January 2026  \nPublished: 24 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa 078-8510, Hokkaido, Japan; [taka-sas@asahikawa-med.ac.jp](taka-sas@asahikawa-med.ac.jp) (T.S.); [ktakaha@asahikawa-med.ac.jp](ktakaha@asahikawa-med.ac.jp) (K.T.); [k-ando@asahikawa-med.ac.jp](k-ando@asahikawa-med.ac.jp) (K.A.);  \n[u-eno@asahikawa-med.ac.jp](u-eno@asahikawa-med.ac.jp) (N.U.); [shin1014@asahikawa-med.ac.jp](shin1014@asahikawa-med.ac.jp) (S.K.);  \n[morimori@asahikawa-med.ac.jp](morimori@asahikawa-med.ac.jp) (K.M.); [tant@asahikawa-med.ac.jp](tant@asahikawa-med.ac.jp) (H.T.);  \n[okumurat@asahikawa-med.ac.jp](okumurat@asahikawa-med.ac.jp) (T.O.); [fjym@asahikawa-med.ac.jp](fjym@asahikawa-med.ac.jp) (M.F.)  \n2 Department of Gastroenterology and Advanced Medical Sciences, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa 078-8510, Hokkaido, Japan; [kyama.kobe@gmail.com](kyama.kobe@gmail.com)  \n[3](3 Department of Gastroenterological Sciences)[ Department of Gastroenterological Sciences](3 Department of Gastroenterological Sciences), [Asahikawa Medical University](Asahikawa Medical University), [Midorigaoka-Higashi 2-1-1-1](Midorigaoka-Higashi 2-1-1-1), Asahikawa 078-8510, Hokkaido, Japan; [ta1983@asahikawa-med.ac.jp](ta1983@asahikawa-med.ac.jp) (T.D.); [sakatani@asahikawa-med.ac.jp](sakatani@asahikawa-med.ac.jp) (A.S.)  \n4 Division of Tumor Pathology, Department of Pathology, Asahikawa Medical University, Midorigaoka-Higashi 2-1-1-1, Asahikawa 078-8510, Hokkaido, Japan; [hiroki-t@asahikawa-med.ac.jp](hiroki-t@asahikawa-med.ac.jp)  \n* [Correspondence: hkonishi@asahikawa-med.ac.jp](Correspondence: hkonishi@asahikawa-med.ac.jp); Tel.: +81-166-68-2462  \nAbstract  \nRNA dysregulation mediated by aberrant RNA-binding proteins (RBPs) is closely associated with tumorigenesis. However, the tumorigenic mechanisms of each RBP remained unclear. In this study, we demonstrate that downregulation of Splicing factor 3A1 (SF3A1) markedly suppressed the proliferation of colorectal cancer (CRC) cells, with minimal cytotoxicity observed in non-cancerous epithelial cells. The tumor-promoting function of SF3A1 was further validated in an HCT116 xenograft mouse model. Multiple apoptosis assays—including TdT-mediated dUTP nick end labeling (TUNEL) staining, poly-ADPribose polymerase (PARP) immunoblotting, and caspase-3/7 activity measurements—showed that SF3A1 inhibited apoptotic signaling in CRC cells. Transcriptome analysis, combined with RNA-immunoprecipitation (RIP), identified Syntaxin 12 (STX12) as a downstream effector of SF3A1 . Knockdown of STX12 induced apoptosis in CRC cells but had no effect on the viability of non-cancerous HCEC-1CT epithelial cells. Furthermore, STX12 mRNA levels were significantly reduced following SF3A1 knockdown, indicating that SF3A1-mediated stabilization of STX12 contributes to apoptosis resistance in CRC cells. Collectively, our findings establish that SF3A1 promotes CRC progression by stabilizing STX12 mRNA and selectively inhibiting apoptosis in malignant cells, thereby identifying the SF3A1–STX12 regulatory axis as a novel and selective therapeutic target for CRC.  \nKeywords: RNA binding protein; colorectal cancer; splicing factor","cbCaiosvpbNBXPwd","https://ap.wps.com/l/cbCaiosvpbNBXPwd","pdf",25351138,16,"English","# Abstract\n# Introduction\n## Molecularly targeted treatments and unmet needs in colorectal cancer\n## RNA-binding proteins in tumorigenesis and therapeutic potential\n## Identifying tumor-promoting RBPs using siRNA screening\n## SF3A1 biology and rationale for investigating its function","[{\"question\":\"How does SF3A1 affect colorectal cancer cell growth and apoptosis?\",\"answer\":\"SF3A1 downregulation markedly suppresses CRC cell proliferation and promotes apoptotic signaling. Multiple apoptosis assays indicate that SF3A1 inhibits apoptosis in CRC cells.\"},{\"question\":\"What downstream molecule links SF3A1 to apoptosis resistance?\",\"answer\":\"Syntaxin 12 (STX12) is identified as a downstream effector of SF3A1. STX12 knockdown induces apoptosis in CRC cells, and SF3A1 knockdown reduces STX12 mRNA levels.\"},{\"question\":\"Why is the apoptosis effect described as selective for malignant cells?\",\"answer\":\"STX12 knockdown induces apoptosis in CRC cells but does not affect viability of non-cancerous epithelial HCEC-1CT cells. SF3A1 also shows minimal cytotoxicity in non-cancerous epithelial cells upon downregulation.\"}]","Splicing Factor 3a Subunit 1 Promotes Colorectal Cancer Growth via Anti-Apoptotic Effects of Syntaxin12 | PDF",1790055285,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ac3ec16d65d7b1486bc4350fe96328ca.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cea3cb4498fe581c2735333eb9ad1a40.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ce68323bbd89d554a4c3671b04d0627.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a56794b86a0fbe46971adba60b65f8ca.webp",980,1385]